Skip to main content

Table 1 Demographic and clinical characteristics of study participants

From: Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure

Variables N %
Age (years) (mean ± SD) 41,1 ± 9,4  
Gender
 Male 135 73,4
 Female 49 26,6
Baseline CD4 count, median (Q1; Q3) 234, 0 (118, 0; 361, 0)  
CD4
  < 200 78 42,4
 200 a 350 50 27,2
  > 350 47 25,5
 Data unavailable 9 4,9
VL (copies/ml), median (Q1; Q3) 19.812,5 (7.036,0; 78.674,2)
VL (copies/ml)
  ≤ 10.000 59 32,1
  > 10.000 a 100.000 75 40,7
  > 100.000 37 20,1
 Data unavailable 13 7,1
∆t on ART (months), median (Q1;Q3) 54, 5 (29, 0; 90, 0)  
Δt in virologic failure
(months), median (Q1;Q3)
17, 0 (10, 0; 34, 0)  
NRTI in failing regimen 184 100,0
 AZT/3TC 126 68,5
 TDF/3TC 48 26,1
 Others 10 5,4
NNRTI in failing regimen 155 84,2
 EFV 135 87,1
 NVP 20 12,9
PI in failing regimen 29 15,8
 LPV/r 16 55,2
 ATV/r ou ATV 400 mg 12 41,4
 Outros 1 3,4
Viral Subtype 171 92,9
 B 139 81,3
 F 31 18,1
 BF 1 0,4
  1. VL = viral load, ART antiretroviral therapy, NNRTIs nonnucleoside reverse transcriptase inhibitors, NRTIs nucleoside/nucleotide reverse transcriptase inhibitors, AZT zidovudine; 3TC lamivudine, TDF tenofovir, EFV: efavirenz, NVP nevirapine, PI protease inhibitor; LPV/r lopinavir/ritonavir, ATV/r atazanavir/ritonavir